Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase I/II clinical trial

被引：0
|
作者：
Zhang, Hongyong
Wang, Yu
Ghosh, Paramita
Lara, Primo N., Jr.
Pasquinelli, Patricia
Beckett, Laurel
White, Ralph W. deVere
Pan, Chong-Xian
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-3720
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3720
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study
    Barata, Pedro C.
    Cooney, Matthew
    Mendiratta, Prateek
    Tyler, Allison
    Dreicer, Robert
    Garcia, Jorge A.
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (06) : 1085 - 1092
  • [32] Results of a phase II study of picoplatin with docetaxel and prednisone in first-line treatment of castration-resistant prostate cancer (CRPC)
    De Jager, R. L.
    Roman, L.
    Lopatkin, N.
    Karlov, P.
    Breitz, H.
    Earhart, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer
    Hussain, A.
    DiPaola, R. S.
    Baron, A. D.
    Higano, C. S.
    Tchekmedyian, N. S.
    Johri, A. R.
    ANNALS OF ONCOLOGY, 2009, 20 (03) : 492 - 497
  • [34] A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer
    Armstrong, Andrew J.
    Shen, Tong
    Halabi, Susan
    Kemeny, Gabor
    Bitting, Rhonda L.
    Kartcheske, Patricia
    Embree, Elizabeth
    Morris, Karla
    Winters, Carolyn
    Jaffe, Tracy
    Fleming, Mark
    George, Daniel J.
    CLINICAL GENITOURINARY CANCER, 2013, 11 (04) : 397 - 406
  • [35] A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer
    Armstrong, Andrew J.
    Shen, Tong
    Halabi, Susan
    Kemeny, Gabor
    Bitting, Rhonda Lynn
    Kartcheske, Patricia
    Embree, Elizabeth
    Morris, Karla
    Winters, Carolyn
    Jaffe, Tracy
    Fleming, Mark T.
    George, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [36] A phase I dose-escalation trial of AEZS-108 in taxane- and castration-resistant prostate cancer (CRPC)
    Pinski, Jacek K.
    Schally, Andrew V.
    Tsao-Wei, Denice D.
    Dorff, Tanya B.
    Groshen, Susan G.
    Xiong, Shigang
    Quinn, David I.
    Tai, Yu-Chong
    Engel, Juergen
    Liu, Stephen V.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [37] Phase I trial of RAD001 (R), bevacizumab (B), and docetaxel (D) for castration-resistant prostate cancer (CRPC)
    Gross, M. E.
    Soscia, J.
    Sakowsky, S.
    Castellanos, O.
    Agus, D. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)
    Hielke J. Meulenbeld
    Johann S. de Bono
    Scott T. Tagawa
    Young E. Whang
    Xiaoyun Li
    Karl H. Heath
    Anthe S. Zandvliet
    Scot W. Ebbinghaus
    Gary R. Hudes
    Ronald de Wit
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 909 - 916
  • [39] Oxaliplatin and docetaxel in castration-resistant prostate cancer (CRPC) patients treated with up to two prior chemotherapeutic regimens: Updated results of a phase II trial
    Chatta, G. S.
    Feinstein, T. M.
    Appleman, L. J.
    Friedland, D. M.
    Jacobs, S. A.
    Evans, T. L.
    Earle, M. F.
    Strausser, H. M.
    Gooding, W. E.
    Lenzner, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study
    Pedro C. Barata
    Matthew Cooney
    Prateek Mendiratta
    Allison Tyler
    Robert Dreicer
    Jorge A. Garcia
    Investigational New Drugs, 2018, 36 : 1085 - 1092
12345